The NZ Skeptics are a voice of reason in New Zealand, and aim to promote the scientific method and evidence-based decision making throughout the public sphere. Healthcare decisions are an important part of this ideal, and we strongly support any measures that seek to follow best evidence and help protect consumers from harm. Thank you for giving us the opportunity to have a say in this consultation.

In a similar manner to the “Pharmacy Council Complementary and Alternative Medicines – Statement and Protocol for Pharmacists”, we will refer to these products as “CAM” and “CAM products” within our submission. However we are hesitant to use this acronym because of its inclusion of the word Medicine, where these products have not proven themselves to be medicines.

1. Can you think of any ethical values for the pharmacy profession that appear to be omitted from the revised code?

Yes.

We believe that the current 2011 Pharmacy Council Code of Ethics, which states (in clause 6.9) that pharmacists must “Only purchase, supply or promote any medicine, complementary therapy, herbal remedy or other healthcare product where there is no reason to doubt its quality or safety and when there is credible evidence of efficacy” is, in principle at least, a good guideline for pharmacists.

Many pharmacies currently supply and promote CAM healthcare products for which there is a very obvious lack of credible evidence of efficacy – even with this code of ethics in place. We are concerned that the general trend in New Zealand has been for pharmacies to sell more CAM over time, presumably driven by a situation where many pharmacies struggle to make enough money to remain viable businesses when selling prescription and over-the-counter medicines alone. An example of this trend is that there is an annual Pharmacy Award for the Best Complementary Healthcare Campaign.

Pharmacists, and pharmacies, enjoy a high level of trust from the public due to their knowledge and expertise, and the importance of the task of dispensing prescription medicines and advising patients that has been entrusted to them. Unfortunately, in order to improve their viability as businesses, many pharmacies appear to have decided to trade on that trust and sell CAM products that purport to improve people’s health, but which do not have good quality evidence backing their use.

The vast majority of these CAM products are unlikely to ever be shown to be efficacious (due the lack of any plausible mechanism of action), and in the short term they are harmless at best – if we ignore their direct financial cost to patients. In the long term, however, these ineffective products are likely to damage patients’ health literacy, making them less knowledgeable about what constitutes good healthcare. They will also tend to make patients less likely to seek proper medical care for their health conditions, instead relying on these unproven products for their future health needs.

If pharmacies find that they need to supplement their income by selling products other than prescription and over-the-counter medicines, there are many products that they could sell that are not health related. We think that it would be much better for pharmacists to avoid the risk of ethically unsound practices, and we would expect the Pharmacy Council’s new Code of Ethics to be an aid in ensuring that pharmacies behave ethically in this regard and do not sell any products that have not been proven to work.

Unfortunately the new code of ethics appears to weaken the stance taken by the 2011 code, rather than strengthening it; only requiring that a pharmacist satisfies themselves that a product is appropriate for the patient (clause 1g).

In essence the proposed new code seems to be worded in a way that, in a perfect world, patients would be protected from the sale of ineffective health products. All pharmacists, and pharmacy staff, would have a good level of knowledge of the evidence base for all CAM products they sold, and they would be free of all biases.

However, in reality, there are a wide range of beliefs about CAM amongst pharmacists and pharmacy staff – and not all of these beliefs accord with the best evidence for these products.

The “secret shopper” exercise undertaken by members of the NZ Skeptics two years ago showed that pharmacies, and pharmacists, are more likely to promote an ineffective product (homeopathic products, in the case of our exercise) than to warn of its ineffectiveness. If the behaviour that we saw in 2015 is indicative of the general stance that pharmacies hold with regard to CAM, and we think that this is a fair conclusion, we believe that pharmacists are often not acting in the best interests of the patient when it comes to CAM. They may not be in possession of the best available evidence, and there is also a real risk that a pharmacy’s need to make money can cloud proper judgement when it comes to selling these products.

For these reasons, we consider that leaving individual pharmacists to be the judges of what constitutes a good level of evidence for a CAM product is not prudent. We believe that it is the Pharmacy Council’s responsibility to help pharmacies navigate the myriad of CAM products that are currently on the market, and ensure that they are not selling ineffective products to patients. We think that the Pharmacy Council should not be scared to provide a robust level of guidance for pharmacists when it comes to both unproven and ineffective CAM products.

We believe that this guidance can be effected in part by creating a list of classes of CAM products that have been shown to be ineffective (such as homeopathy), and which should not be sold in pharmacies. The Pharmacy Council should also target the most popular CAM products being sold in pharmacies, and create information resources for both pharmacists and patients explaining the current evidence, or lack of evidence, for these products. These resources could include booklets that are made available in pharmacies, and given out when these products are purchased, and web pages that are placed online, either on the Pharmacy Council’s website or a site specifically for providing information about CAM products.

2. Considering the explanation of the term “patient” and equivalent terms in the key terms (key terms):

a. Do you think the term “patient” is the best word to use, most of the time, to express the relationship that exits between the pharmacist and the person they are directly or indirectly caring for or providing health care information to?

Yes.

We think that the word “patient” is a positive step towards impressing on pharmacists the importance of the relationship they have with the public, and the trust that the public place in pharmacists to behave in a way that is in individual patients’ best interests.

b. Are there any specific clauses where you can think of different term that could be more appropriate?

No

3. Considering the new clauses that relate to the sale of complementary and alternative medicines (CAM, clauses 1g, 4h and 4hh): Do you find it clear that the Council is not opposed to the sale of CAM when they have demonstrated benefits for patients, have minimal risks, and the patient is making an informed choice?

No.

We think that the clauses do not make it clear that they are not opposed to the sale of CAM “when they have demonstrated benefits for patients, have minimal risks, and the patient is making an informed choice”. What the clauses appear to do, instead, is to allow the sale of CAM when an individual pharmacist believes that these products “have demonstrated benefits for patients, have minimal risks, and the patient is making an informed choice”.

This is a subtle, but important, difference. We think that the proposed code would allow for a pharmacist to sell homeopathic products, for example, simply by holding a sincere belief that these products “have demonstrated benefits for patients, have minimal risks, and the patient is making an informed choice”. This belief would not accord with reality, but merely holding it appears to be sufficient to circumvent this code.

To paraphrase the songwriter Tim Minchin, “what do you call Complementary and Alternative Medicines (CAM) that have demonstrated benefits for patients? Medicine”

4. Are there any other comments you would like the Council to consider?

Yes.

We would like to see the Pharmacy Council produce a set of clear rules for when a product can be deemed to be ineffective; a clear, transparent process outlined for dealing with complaints against pharmacies selling products that are not evidence based; and clear penalties for pharmacies that are found to be in breach of these guidelines. The new code does not appear to allow for this to happen, and instead we suspect that it is unlikely that the Pharmacy Council will end up using this new code to censure a pharmacy for selling ineffective health products.

We would be interested to find out, given the many apparent breaches of the current code of ethics where pharmacies are selling CAM without credible evidence of efficacy, how often pharmacies have been found by the Pharmacy Council to be in breach of the code, and what action was taken in each case.

We would also like to see the Pharmacy Council introduce a way to effectively measure whether pharmacies are following the code of ethics – some method of proactively auditing the compliance of pharmacies. These checks would have to be incognito, to ensure that an accurate measure is taken of how pharmacies are promoting CAM to patients.

Fluoridation

The NZ Skeptics believe that the available scientific evidence shows community water fluoridation to be both a safe and effective measure for reducing incidence of tooth decay. What we see in the behaviour and tactics of the anti-fluoridation movement in New Zealand echoes similar behaviour we see from other ideologically anti-science groups, such as the anti-vaccination movement. This includes “cherry picking” of only the evidence that supports their position while ignoring any data to the contrary, misrepresenting scientific studies, and flouting New Zealand regulations in order to misinform the public.

 

We believe that the anti fluoridation movement has come out against this bill not because they believe that local councils are better able to make healthcare decisions for the public, but because it is easier for them to influence and subvert these decisions when they are made at a local council level – as we have seen them do in the past.

The Proposal

The NZ Skeptics support the proposed change of moving the decision to fluoridate water supplies away from local councils, and transferring it to District Health Boards

As water fluoridation is a public health measure, we believe that DHBs will be better suited to make an informed decision than local councils are. DHBs have staff on hand who are proficient in reading and analysing scientific studies, and they also monitor the health of their district’s residents. These two skills will allow DHB staff to advise the Board members of each DHB as to whether fluoridation is an appropriate measure.

Other agencies

We would like to note that if a change is made to move the decision making process to central government rather than to DHBs, we would be supportive of this move.

 

Thank you for the opportunity to be able to give our opinion on the proposed change to this important health measure.

The Medical Council asked for submissions on a proposed amendment to their statement on advertising in relation to the use of testimonials, with the amendment prohibiting the use of testimonials by doctors in advertising. The consultation asked three questions, and here are the answers that the NZ Skeptics gave:

 

1. Do you agree with Council’s proposed prohibition of the use of testimonials in medical advertising? Why or why not?

We agree. Testimonials are by their nature anecdotal, and as such their use in medical advertising is problematic for a number of reasons. These can be summarised by stating that it is impossible to imply any meaningful evidence of efficacy from a testimonial.

Although testimonials do not demonstrate the efficacy of a treatment, or the ability of a doctor, they do tend to influence a patient’s choice. Many patients will not understand the distinction between evidence and testimonials, and could easily be led to assume that a testimonial is direct validation of a medical service. Evidence offered to aid a patient’s choice, in the form of well designed trials, systematic reviews and meta analyses, should be the kind of supporting evidence offered by a medical practitioner. Prohibiting testimonials would serve to eliminate a potential emotive factor from a patient’s choice, leaving them with the confidence that they have not been unduly influenced in this way.

The widespread use of testimonials by ‘alternative’ medicine practitioners (those that have no scientific evidence or plausibility) is of interest, since it would appear that testimonials might be the last bastion among these practitioners – those that have no other avenue with which to suggest that their services work, except to solicit previous customers who are persuaded by their own experience to write testimonials.  Of course testimonials can be, and often are, ‘cherry picked’ by alternative medicine practitioners, so that only the positive testimonials are shown.

If testimonials were allowed to be relied upon to persuade patients to seek treatment from a medical doctor, there could never be certainty that the true balance of testimonials was in favour of the medical service. Intellectual dishonesty, amounting to data manipulation, could never be ruled out.

Additionally, any tendency for wishful thinking and the “I’ll try anything” rationale, which is human nature (especially among seriously ill patients), is particularly susceptible to the use of testimonials.

 

2. Do you agree with Council’s proposed definition of ‘testimonial’? What other changes (if any) should Council incorporate in its definition of ‘testimonial’?

For the most part, we agree. However we would like to offer a few suggestions.

Firstly, Footnote 7 states “you are not responsible for any unsolicited testimonials or comments that are published on a website or in social media over which you do not have control of”. This seems like a possible loophole, and we wonder if wording about taking reasonable steps to prevent or remove such unsolicited testimonials should be included here. Clearly practitioners should not be held responsible for things said out of their control. However, a less scrupulous practitioner might use this exemption to circumvent the prohibition of testimonials by keeping themselves separated from the direct process of solicitation, perhaps via the use of a proxy.

Secondly, the proposed definition refers specifically to “a doctor’s care, skill, expertise or treatment”. However some websites, such as that of the Apollo Medical Centre (http://www.apollomedical.co.nz/testimonials.php), include testimonials that refer to the centre as a whole rather than to specific named doctors. The following testimonial from ‘Sarah’ is an example of this:

“When I came to Apollo Medical as an acute patient visiting from Wellington, I felt self assured and confident that I was getting very good care.  Everything ran very smoothly with my visits being followed up by the nurse and the results clarified by the doctor.  When it is not your regular medical centre you do feel quite vulnerable, but at Apollo I felt very well cared for, even though I was not a regular patient.  Everyone was very pleasant and kind, and I would not hesitate to go there again if needed.” [Emphasis added]

Sarah refers to her feelings about the quality of care that she received from the medical centre as a whole, including at least one nurse and doctor. It’s unclear whether this type of testimonial would fall under the definition given by the Medical Council, and we suggest rewording to extend the clause to cover testimonials where doctors are a part of the group being endorsed, to the extent that they have control over this advertising.

 

3. Are there any other changes that Council should incorporate to Clause 13?

Yes, we would like to see Council include a sentence such as “Doctors should not solicit patients to submit testimonials to third party websites” in Clause 13, or alternatively in Footnote 7.

 

Below is the NZ Skeptics’ submission on the recent Regulation of Natural Health Products consultation, run by the Ministry of Health. The consultation is related to the Natural Health and Supplementary Products bill, which is likely to become a new piece of New Zealand legislation in the near future. Our submission is a point by point response to the questions raised by the consultation document, which can be found, along with supporting documents, at:

http://www.health.govt.nz/publication/regulation-natural-health-products-consultation

 

The Regulation of Natural Health Products

 

Ingredients

 

1. Are there other criteria that the Committee should consider when adding a substance to the permitted substances list?

Yes. Possible interactions with both prescription pharmaceuticals and other natural health products should be considered when adding a substance to the permitted substances list.

A history of safety issues and patterns of historical misuse of a substance should also be considered. This history should be gathered from reliable sources located globally, not just in New Zealand.

 

2. Of the criteria proposed, are there any that you think should not be considered by the Committee when adding a substance to the permitted substances list?

No. All of the proposed criteria appear to be important for ensuring the safety of substances, and we hope that they all become part of the final criteria used to evaluate substances.

 

3. Should the criteria to be considered by the Committee be weighted or ranked in some way?

Yes. Concern for safety is paramount, so any safety assessment should hold increased weight.

 

4. Do you agree that full formulation details of proprietary ingredients should be disclosed?

Yes. We wholeheartedly agree that full formulation details should always be disclosed to both the Authority and consumers. The safety of consumers relies on all ingredients and amounts being known, and matters of consumer safety should always trump those of commercial interest. We also believe that for consumers to be able to make informed choices about their healthcare, they have a right to know the ingredients of any healthcare product they are taking.

 

5. Are there substances that could be added to or should be removed from the draft permitted substances list?

Yes. Although we did not have the resources to check through the entire list of draft permitted substances, we were very surprised at how long the list was. Ideally we would like to see all substances, outside of those with a proven therapeutic benefit, having to go through a submission process which involves the paying of a fee, rather than automatically being added at no cost. This ensures that due diligence is performed on all substances.

Health benefit claims

 

6. Are the following factors the right ones to consider when deciding if claims may be made about named conditions:

• non-serious
• self-limiting
• suitable for self-management
• suitable for self-diagnosis
• likely to cause serious consequences without health practitioner consultation?

Yes. These are a good minimum set of conditions. No claims should be made for conditions that do not take into consideration all of these factors. These factors would benefit from being turned into a more formal, precise set of rules, to ensure they are consistently applied to all potential allowed conditions.

 

7. Should other factors be considered?

Yes. We believe that conditions should only be added to the allowed list if it has been found by the Authority that at least one natural health product has been shown to be effective in treating the condition. This would go some way towards showing a plausibility for other natural health products also having the potential to have a positive effect on the condition.

 

8. Should the factors be weighted or ranked in some way?

Yes. The factors that have a more direct effect on consumer health risks should be ranked higher, e.g. the seriousness of the condition.

 

9. Are there conditions you think should be added to or removed from the draft list of conditions about which health claims may be made?

Yes. There are several items on the list of conditions that are prefixed or suffixed with “unspecified”, such as “bacterial infection unspecified” and “allergy, unspecified”. We wonder if some of these definitions are too broad, and should either be removed or replaced with specific conditions.

We recommend that time is spent on ensuring this list is acceptable to a range of health professionals (accredited medical science health professionals, rather than alternative therapy professionals) and any relevant professional bodies (again we would prefer to see no alternative therapy professional bodies involved, given their conflict of interest).

We would also like to see an explicit provision for the regulations about health claims to include any claims made within the name of a natural health product. We are concerned that some products currently have names which make health claims, including naming specific medical conditions in the product name. Examples of products sold in New Zealand with this issue are:

• Tea Tree Face Wash for Acne
• Allergy Relief
• Complete Sleep Formula
• Cholesterol Guard
• Painex
• Cold & Flu Fighter

Evidence

Relevance and representativeness of evidence

 

10. Are there other criteria that should be included, or should any of the listed criteria be excluded?

Yes. We think that it is not enough for evidence to “not conflict with a wider body of evidence”. It would be better to have the reverse of this criteria, that evidence should “agree with a wider body of evidence”. This strengthens the criteria to ensure that a single study would not be considered sufficient evidence, in cases where there has been a lack of research conducted on a product’s efficacy.

Traditional evidence

 

11. Are these appropriate sources of traditional evidence?

No. Ideally, there should be no mention of historical use when it comes to the marketing of natural health products and no claims should be able to be made about a product on the basis of this traditional evidence. Our understanding is that historical use does not have a good track record when it comes to proving either that a product is able to treat a medical condition, or that the product is safe. The vast majority of natural health products with evidence of historical use to treat a condition have either a) not been proven to actually treat the condition or b) been positively shown to not treat the condition.

At least some consumers are likely to be led to believe that evidence of historical use is evidence of efficacy. If this information is allowed to be used in any way for making health claims about a product, those consumers will be misled into thinking that the product is able to treat a health condition. This should be enough of a reason to ensure that historical use is not allowed to be used as evidence for a natural health product.

It is telling that the section on traditional evidence in the guidelines is so much shorter than the section on scientific evidence. The scientific method is a well tested way of testing whether claims are true or not, and as such it is necessarily strict about how scientific tests are conducted and what can be considered an acceptable level of evidence. Traditional evidence, on the other hand, is not encumbered by a requirement to prove that its claims are true – merely that its claims are old. Accepting traditional evidence, in any form, is enacting a great disservice to New Zealanders, who rely on the government to ensure they are protected from ineffective or dangerous treatments.

If historical use will be allowed as evidence, there are some issues that we have with the guidelines.

We do not believe that an individual should be taken on authority when making claims about whether there is evidence of traditional use for a treatment. Written documented evidence of historical use should be a bare minimum accepted, and this should be evaluated critically before being accepted. No matter what the position of an individual in a culture, their claims should be subjected to scrutiny – arguments from authority should not be accepted.

We are also worried about the pharmacopoeia that have been listed. We believe that these should not be taken on face value as evidence of traditional use, and that external validation of their claims must be required. Obviously, for any volume first published before the traditional use time period, this would be sufficient evidence that the treatments listed within the volume fit the criteria of traditional use. However, we are concerned that some of these pharmacopoeia may contain treatments that have only relatively recently been used.

In fact, any single source that claims historic use of a natural health product should not be taken at face value. Multiple independent forms of evidence should be required before it is accepted that a product has a long history of use.

 

12. Are there other sources of traditional evidence that should be accepted?

No. We are concerned that the existing sources of traditional evidence are already too broad, and that the average consumer will give traditional use claims more weight than they merit. Adding more sources would only exacerbate this problem.

 

13. Do you think 75 years is an appropriate minimum period of use for something to be considered to be traditionally used?

No. We consider that use should only be considered as traditional if it pre-dates the spread of the scientific method in medicine. A useful yardstick for this date is the publication of An Introduction to the Study of Experimental Medicine by Claude Bernard in 1865. At the very least, we believe that a fixed date should be chosen for deciding if something has been traditionally used, to simplify management of which treatment types are considered to qualify or not qualify. If a time period is used (e.g. 75 years), the Authority will need to track when treatments change from not qualifying as being traditionally used to qualifying. Given the large number of natural health products available, this could be burdensome task.

Scientific evidence

 

14. Are there other factors we should consider when determining if a type of study is acceptable?

Yes. The guidelines suggest linking the level of study considered acceptable as evidence with the risk of using a product. We do not consider this to be a sensible position to take. The level of evidence required should not be linked to the risk of taking the product, but only to the level of claims being made about the product. The more specific and definite the medical claims, the higher the level of evidence that should be supplied. Whether the product is low or high risk, however, should not influence the level of evidence deemed acceptable.

We consider that peer review is an absolute minimum for deciding that a type of study is acceptable. Allowance will have to be made for the varying quality of peer reviewed journals, especially given the proliferation of unscrupulous journals in recent years that have been known to compromise on peer review. A good overview of this issue can be read at http://science.sciencemag.org/content/342/6154/60.full

 

15. Are the types of studies that are acceptable clear?

No. It is not clear that all the types of studies listed have a requirement that they are peer reviewed. We believe that this requirement is important and should be explicitly mentioned.

 

16. Should other types of studies be considered acceptable?

No. Some of the existing list of types of studies considered acceptable are already at what appears to be a lower standard than would be acceptable to MedSafe or the Advertising Standards Authority as evidence of efficacy. Any further adding of acceptable types of studies would only risk weakening this consumer safeguard.

Summary of evidence

 

17. Are the evidence guidelines clear?

No. The Draft Guidelines for Natural Health Products Evidence Requirements document contains several worrying details.

There is a statement that “Scientific evidence does not take precedence over traditional evidence”, in the General requirements for evidence section of the guidelines. We are concerned that it is not clear from the document what reasoning has been used to discern that traditional and scientific evidence are equal in this way.

It is our understanding that science has made great strides in providing us all with affordable, effective healthcare, whereas most traditional treatments have not been adopted by modern medicine precisely because they have not been shown to be effective. To equate the two forms of evidence is to totally ignore the fact that the scientific method has proven itself time and time again, and has earned the right to be considered a more trustworthy way of proving a claim than has the simple idea that something has been used for a long time. Many treatments that have a long history of use are now known to be dangerous, such as bloodletting and purging.

Given that evidence of traditional use is, in effect, evidence that a treatment was developed when we were a lot more ignorant that we are now about medicine and healthcare, we strongly resist the idea that the two should be given equal footing.

This principle of not accepting scientific evidence over traditional evidence leads to the unfortunate statement later in the guidelines that “Traditional claims that have been scientifically proven not to be correct can still be made”. We believe that this is unacceptable, and that if there is good quality positive scientific evidence to show that a claim is false, that claim should not be allowed to be made at all – including in the context of historical use.

We believe that all evidence should be available in English. The guidelines state that “The evidence that you hold to support your claim must be in English, or you must be able to provide a verified English translation if requested by the Authority.“ We believe that it is important to allow consumers to be adequately informed, and as such an English version of any evidence held should always be made available in an easily accessible format.

We would like to see provision made for consumers to have access to the full text of any studies cited in support of a health benefit claim. It would be disappointing to have natural health companies making claims that cannot be readily verified because the studies cited are locked behind a paywall and out of reach of consumers due to the cost involved. Given how often we have seen natural health companies claim that a study supports their position, where a subsequent reading of the text has shown that the company has either accidentally or deliberately misconstrued the results of the study, we feel that making it easy for consumers to verify a given summary of a scientific text would be beneficial.

The list of health benefit claims given in the guideline are inclusive, which is laudable. The five claims given are:

• maintenance or promotion of health or wellness
• nutritional support
• vitamin or mineral supplementation
• affecting or maintaining the structure or function of the body
• relief of symptoms.

Given these definitions, we hope that the new regulations will cover the types of claims that are currently exempted by TAPS Guideline 13, such as:

• Helps smooth digestion
• Aids the digestive process
• Supports normal digestion
• A natural approach for digestion

We believe that these claims are all likely to mislead consumers into thinking that a product is effective for a given health condition, and as such the new regulations should require evidence for these claims.

For products that come under the purview of the new regulations, we would like to see provision to ensure that companies don’t deliberately use vague claims to avoid having to supply supporting evidence. For example, non-specific claims about “the immune system” or “mental wellbeing” should not be allowed.

 

18. Are there other evidence-related topics that should be included in these guidelines?

No.

Manufacturing

The Code of Manufacturing Practice

 

19. Do you agree with the proposed Code of Manufacturing Practice?

No. We have problems with the general thrust of the Code, as it is summarised in the consultation document.

We see no reason for there to be any gap between the legislation and the Code of Manufacturing Practice coming into force. We hope and assume that most natural health product manufacturers are already following a code of manufacturing practice that is closely aligned with the proposed new Code, and so meeting the requirements of this Code should be a quick and simple task.

We also strongly disagree with the principle that the manufacturing regulation of natural health products should be proportionate to the risks of their use. We feel that manufacturing risks are independent of the risk of a product’s use, as these risks come from outside of the intended use of a product. For example, contamination of a product is an equally risk-laden issue whether the product itself is considered low risk or high risk .

Manufacturing exemptions

 

20. How frequently should audits be required? Should this differ for different levels of risk?

We agree that it is acceptable for audit frequency to depend on risk. We think that the risk level should be informed by such measurements as the history of a manufacturer’s prior infringements and the compliance history of the product with other manufacturers.

We do not agree that there should provision for any manufacturer to be exempt from auditing.

 

21. Do you think there should be exemptions from manufacturing licensing?

No. If anything, small volume manufacturers of natural health products have a greater potential to create products that carry risk. All consumers deserve the same protection, whether they are purchasing a product from a high volume manufacturer or a small scale manufacturer.

Fees

 

22. Are these the right things for the Authority to charge for? Are there other things for which the Authority should charge?

We are not concerned with the services that the Authority will charge for.

 

23. Are the charges structured appropriately?

We are not concerned with the structure of the charges.

 

24. Do you have any comment on the proposal that notification be for a July–June financial year, and/or the proposals to handle the transition period?

No.

 

25. Do you have any comment on the level of the charges?

Yes. Although we have no specific recommendations for fees, we believe that overall the annual amount collected in fees should be sufficient to fund a robust system of proactive regulation. These fees should allow for:

• Frequent manufacturing audits
• Random manufacturing spot checks
• Independent product checks to ensure the accuracy of both the ingredient list and listed dosages
• Frequent evidence checks for evidence supplied in product notifications
• The use of qualified scientists in relevant fields to evaluate supplied scientific evidence

Ideally, we would prefer to see the product registration system as an approvals based system rather than a notification system. We think that an enforced check of all product registrations should be performed, and that the natural health products industry should bear the cost of this process via product registration fees.

We would like to see the Authority make provision for a robust, proactive, transparent complaints procedure. Ideally this procedure would involve the proper consideration of all complaints laid before it, rather than a cherry picking of only those complaints deemed to be the worst offences. We would also like to see this procedure made as transparent as possible, with the complainant kept informed at all stages of a complaint’s processing, and information on complaints and their outcomes made public on a website. The website should also allow for online complaint filing, and have clear instructions on how to make a complaint and what kinds of issues merit a complaint.

 

26. Do you have any comment on the assumptions around volumes each year? Would you expect higher volumes in the first year?

No.

 

27. How many products do you anticipate notifying initially, and in the next two to three years?

No, we have no expectation around this.

 

28. Do you agree that manufacturers are best placed to commission any quality control activities, such as audit, that might be required by the Code of Manufacturing Practice?

No. We consider that allowing product manufacturers to self audit is taking an unacceptable risk. Natural product manufacturers should not be trusted to be able to effectively police themselves, especially given the global track record for natural products failing to conform to their stated ingredients lists:

• http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-222
• http://www.bbc.com/news/health-33504210
• http://www.ag.ny.gov/press-release/ag-schneiderman-asks-major-retailers-halt-sales-certain-herbal-supplements-dna-tests

 

29. Are there additional issues relating to fees and charges that you would like us to consider?

No.

Very low-volume products

 

30. Do you see a case for reducing fees for very low-volume products?

No. Fees should be reduced in circumstances where it can be shown that associated costs are lowered. However, we do not see how a low-volume product would entail a lower cost to the Authority in managing the product registration, and so we do not believe that these products should qualify for reduced fees.

 

31. How would you define very low-volume products?

We believe that any natural health product, even one that is custom made for a consumer with a volume of only a single unit, should be regulated. Therefore, although we have no recommendation of an upper limit for what is considered low-volume, our lower limit would be 1.

 

32. Do you have any suggestions for the design of any provisions, including:

• limits on the number of products that any notifier can have fee exemptions for
• administrative efficiency
• any other issues that might be associated with low-volume products?

 

No.

Labelling

 

33. Do you agree that labels should meet the proposed presentation requirements?

Yes. There should be a procedure in place to ensure all labels meet the requirements before a product can be sold, and a process for consumers to report products that fail to meet the labelling standards.

 

34. Are the proposed minimum labelling requirements the right ones?

Yes. The labelling requirements are well thought out, and will help to protect consumers through allowing them to be sufficiently informed about the product.

 

35. Should product labels include unique identifiers?

Yes. Unique identifiers should be on all labels, and there should be provision for this identifier to be searchable in an online product database of all registered natural health products.

Given the proliferation of internet enabled smartphones, we would like to see this process made as simple as possible by the inclusion of a QR code on labels as an added unique identifier. This code, when scanned by the consumer’s smartphone camera, would open the product registration webpage in a browser on the consumer’s phone. The technology to allow this to happen is already freely available, so the cost to add this feature would be minimal.

The unique identifier section of a label could look like this example:

 

36. Is there any other information that should be included, or should any of the listed information be excluded?

Yes. We believe that intended purpose of the product should only be allowed to be included on the label if there is scientific evidence to underpin the claim. We do not consider historical evidence alone to be sufficient to warrant the inclusion of a claim that the product is able to treat any medical condition.

If evidence of historical use is allowed to be included on product labels, we believe that it should be accompanied by a disclaimer which explains that the claim does not constitute evidence of efficacy. The disclaimer could take the form of:

Traditionally used for x. This is not evidence that this product is able to treat any medical condition, only that it was believed to do so in the past.

Notification

 

37. Is there information that you think should be included in, or excluded from the notification process?

Yes. We think that, along with the summary of evidence, a summary of risk should be included. Manufacturers should be expected to have researched any risks associated both with each active ingredient and with the formula of ingredients. Any adverse effects recorded in medical journals or databases from around the world should be summarised and included in the report, along with links to the source data.

 

38. What information that we are proposing be notified do you think should not be made publicly available and why?

None. We believe that full transparency is important to allow consumers to make an informed choice about their healthcare.

 

39. Should products that sell in less than a certain quantity per year be exempt from notification?

No. We believe that any exemption to notification is a risk. If exemptions to notification are to be allowed, this should be related to risk. We do not consider the quantity sold to be a reliable indicator of reduced risk to the consumer.

 

40. Should products for which the annual sales amount is less than a certain figure per year be exempt from notification?

No. Similarly to question 39, We do not consider the annual sales amount to be a reliable indicator of reduced risk to the consumer.

 

41. Should exemptions on other grounds be considered?

No. We think that the exemptions listed in the consultation document, for one-off products and homeopathic products, will both increase the risk to consumers. The only way to ensure that these products are safe is to subject them to the same regulations as other natural health products.

The three main risks with natural health products, as defined in an overview at the beginning of the consultation document, are that:

1. The ingredients in the product could be unsafe.
2. Consumers may delay seeking conventional medical treatment.
3. Products could be manufactured in an unsafe way.

We consider all of these risks to apply to both homeopathy and one-off products, as much as they do to other natural health products.

For example, with homeopathy, the only way to ensure that an active ingredient has been diluted to the point that it is safe, and that there no contaminants due to unsafe manufacturing, is to test the product. An easy way to ensure the safety of homeopathic products is to not exempt it from the regulations. Failing that, there should be provision that exempted products carry a warning that they are not covered by the regulations. This warning could look like:

This health product has been exempted from regulation by the Natural Health Products framework. Any health claims made by this product have not been vetted in any way.

We are concerned that if homeopathic and other exempt products are not covered by the new regulations, consumers will assume that they are covered and will not notice the lack of regulatory labelling on these products. As such, the warning above would need to be made obvious on the packaging.

Homeopathy is well known as a natural health product that has caused consumers to delay medical treatment. A website called What’s the Harm has documented some of these cases from around the world at http://whatstheharm.net/homeopathy.html

 

42. To be fair to all product notifiers, how should requests for exemptions be verified to ensure they actually qualify?

We believe that exemptions are anathema to the idea of ensuring consumer safety. We hope that no ad hoc exemptions would be accepted, as they would allow a product to bypass this scheme – a scheme which is rightly designed to protect consumers.

Recognised authorities

 

43. Are there any additional purposes for which you think the Authority should also consider recognising other authorities?

Yes. We would be happy for other authorities to be recognised for several purposes, as long as those authorities can be shown to be both impartial and proficient. The purposes we think are suitable are:

• Analysis of any health claims being made
• Testing of product ingredients
• Manufacturing spot checks

 

44. Are there any purposes for which you think the Authority should not consider recognising other authorities?

No.

 

45. What other authorities do you think the Authority should recognise and for what purpose?

As we have said previously in this submission, we believe that product registration should be an approvals rather than a notification system. We think that MedSafe would potentially be a proficient authority for tasks such as analysing the scientific evidence for product approvals.

Determining if your product is a permitted natural health product

 

46. Does the flow chart to determine if your product is a permitted natural health product make sense to you?

Yes. We wonder if an interactive version of this flow chart would be a useful addition to a Natural Health Product website that we presume will be created – maybe a list of questions with Yes/No buttons to answer them.

 

47. Are there other considerations that we should take into account?

No.

Other Issues

We hope to see the Natural Health Products website become a useful resource for finding information about all information useful to consumers, such as registered products (including full ingredients, the evidence summary, etc), deregistered products, permitted substances, allowed conditions, consumer complaints and manufacturer fines. To that end, we would like to see that an API is placed in front of this data to allow easy access, in accordance with the government’s commitment to Open Data. We also hope to see the website make use of modern technologies such as responsive design and Microdata, along with extensive hyperlinking, to make the site intuitive and easy to navigate on handheld devices as well as full sized computer screens.

We thank the Ministry of Health for giving us the opportunity to submit our thoughts on this new, important piece of legislation. We hope that our ideas are helpful in finalising the specifics of the bill and associated guidelines, and we would be keen to engage further with the Ministry on this topic in any way that we can help.

Submission relating to proposals by the Pharmacy Council to alter Clause 6.9 of the code of Ethics

I am Edward Linney a consumer with an active interest in evidence based medicine.

I do not support the intent of clause 6.9b to avoid a requirement of credible evidence of efficacy for complementary therapy or other healthcare products.

Extract from consultation document

Proposed supplementary wording – two distinct parts – clause 6.9

6.9a     “Only supply or promote any medicine or herbal remedy where there is no reason to doubt its quality or safety and when there is credible evidence of efficacy.”

 

6.9b     “Only supply any complementary therapy or other healthcare product where there is no reason to doubt its quality or safety and when sufficient information about the product can be provided in order for thepurchaser to make an informed choice with regard to the risks and benefits of all the available treatment options.”

 

The addition of 6.9b explicitly avoids any requirement for there to be credible evidence of efficacy. It moves the roles of evaluation of scientific evidence from the scientists to the consumer. This is bizarre, we all understand that the patient purchasing the homeopathic remedy for example is a believer and is most unlikely to be able to make an informed decision in the complex task of selecting the best products to treat themselves with.

Pharmacies are businesses BUT they are run by scientifically qualified people and they trade on this image. They are the only place where the public can purchase prescribed pharmaceuticals. Pharmacists enjoy a very privileged position in that regard. In my view the public expects you to sell and promote products which are shown in appropriate testing to perform better than a placebo, in short evidence based products.

The National Health and Medical Research Council of Australia ( The Government if you will) published an unqualified opinion in March 2015 after wide public consultation and a meta analysis of many trials that homeopathy is no more effective than placebo in treating humans. It comes as no surprise to me that when the credibility of these products which are actively promoted and sold in all my local pharmacies is vanishing that the Council proposed to avoid the requirement for efficacy in the sale of these to the public by pharmacies.

I believe there is a connection between the growing awareness that homeopathic remedies are placebos and the intention to explicitly avoid efficacy in the code of ethics in relation to their sale in pharmacies. It is a business protection step taken now to ensure that members of the public cannot take pharmacies to task for breaches of their code of ethics.

I submit it is totally unethical for the Council to put in place a provision whereby a scientifically trained seller uses that credibility to then sell known placebos as if they have efficacy. It is a betrayal of the science that trained them and a cynical exploitation of their status as health professionals. I wonder if pharmacists will have a warning label on these products which states they have NO active ingredients and they are no more effective than placebos. Perhaps the Council, if it wishes to see pharmacists selling these products should insist on a step like this, that would be the truth and assist the informed choice you are advocating. It was not so long ago that the pharmacies used to say “the health professional you see most often”, sadly you cannot make this claim today given current practice in selling known placebos.

It is telling that the consultation document suggests not promoting or recommending products which lack efficacy but is unwilling to take the ethical step of including efficacy explicitly in the code. It is simply duplicitous and puts commercial gain ahead of evidence based operations in patient and public outcomes.

The Council should retain the requirement at all times when selling products that claim to assist medical situations that there MUST be credible evidence of efficacy. Not to do so is in breach of the duty of Council to promote good practice and protect the public by being complicit in the public opting for remedies which are placebos and thereby not using genuinely efficacious products that have been proven by proper trials. The patient outcomes are likely worsened if a placebo is used in place of the best treatment.

Pharmacies seek to be taken seriously and want to expand on their offering in the evidence based market by adding things like Wharferin testing for example. They cannot have it both ways they are either just a peddler of anything the public wants or are serious health professionals. Your decisions in this matter will answer that question.

Edward Linney

Submission to the Pharmacy Council’s 2015 Code of Ethics Consultation

The Pharmacy Council’s Code of Ethics 2011 appears to be a well written document which puts the wellbeing of the patient front and centre. This can be seen throughout the code, and is embodied in the very first clause:

1.1 Take appropriate steps to optimise medicines-related health outcomes for the patient as a fundamental principle of pharmacy practice.

The existing clause 6.9 of the code gives a good level of protection to patients, in that it states that pharmacies should not supply products where there is a lack of evidence of efficacy.

6.9 Only purchase, supply or promote any medicine, complementary therapy, herbal remedy or other healthcare product where there is no reason to doubt its quality or safety and when there is credible evidence of efficacy.

In the Pharmacy Council’s Consultation Document, the proposed new wording of clause 6.9 of their Code of Ethics splits healthcare products sold in pharmacies into two broad categories:

• medicine or herbal remedy
• complementary therapy or other healthcare product

The reason for this split appears to be an effort to relax the code for the second class of products (complementary therapies and other healthcare products). Effectively, this would remove the code’s requirement for there to be “evidence of efficacy” before these products can be supplied by a pharmacist. Instead, the new code only requires that “sufficient information about the product can be provided”. As it stands, the existing code appears to be in place to protect patients – any weakening of the code is going to reduce this protection, and that can only be a bad thing.

The Pharmacy Council’s vision is “Safe Effective Pharmacy Practice”. We believe this proposed change in the Code of Ethics would compromise the “Effective” part of this vision, by making it more likely for individual pharmacies to sell products that do not meet any reasonable standards of credible evidence, and could therefore be reasonably considered to be ineffective.

In the “Background” section of the consultation document, the Pharmacy Council says:

Over a number of years there has been much debate and discussion regarding the  promotion, supply and sale of complementary and/or alternative medicines by pharmacists. This debate has primarily focussed on the efficacy of these therapies.

Given that most pharmacies appear to sell at least some complementary/alternative health products, we presume that this debate and discussion has been around whether pharmacies should stop selling these unproven remedies. The document goes on to say that “Over the past 12-months the level of sector and public interest has notably increased”.  We are glad to hear that the Pharmacy Council is aware of the concerns people have about the sale of alternative health products, but are concerned that their proposed solution, although it is technically a “fix” for the problem, is a step in the wrong direction.

The Pharmacy Council is faced with the issue of pharmacies’ actions conflicting with their Code of Ethics, and changing the code appears to us to be the wrong choice out of the two obvious options the Council has to choose from to help resolve this conflict. Instead of relaxing their Code of Ethics, we think that the Pharmacy Council should instead consider either putting in place an effective program that is able to ensure pharmacies are abiding by their existing Code of Ethics, or delegate this important function to another organisation that is better suited to the task. We think that a code of ethics that carries no incentive for compliance is not a code that is likely to be adhered to. The following paragraphs show that the existing code has not been followed by what appears to be a significant number of pharmacies, and that there is a need for active management of compliance to the code.

We have a concern that the Pharmacy Council’s expectation that “Pharmacists should be able to advise patients about the general use, current state of evidence, associated effectiveness and any safety issues relating to complementary and/or alternative medicines” is unrealistic given the current state of the pharmacy industry, and as such we tasked people around New Zealand with visiting their local pharmacy to ask about homeopathy. We chose homeopathy because there is a strong scientific consensus that homeopathy has no efficacy beyond the placebo effect, and there is no plausible mechanism of action:

“NHMRC concludes that there are no health conditions for which there is reliable evidence that homeopathy is effective” – Australia’s National Health and Medical Research Council

“Pharmacists should not sell, recommend, or support the use of homeopathic products” – Royal Australian College of General Practitioners

“PSA does not support the sale of homeopathy products in pharmacy” – Pharmaceutical Society of Australia

“The Royal Pharmaceutical Society believes that there is no evidence from randomised controlled trials for the efficacy of homeopathic products beyond a placebo effect, and no scientific basis for homeopathy“ – UK Royal Pharmaceutical Society

“By providing homeopathy on the NHS and allowing MHRA licensing of products which subsequently appear on pharmacy shelves, the Government runs the risk of endorsing homeopathy as an efficacious system of medicine” – House of Commons Evidence Check

“it’s an ineffective treatment. It’s basically giving a glass of water or a sugar pill to patients, and I think you would consider that unethical” – New Zealand Medical Association Chair

We found that around half of the pharmacies visited had staff that were willing to promote or supply homeopathic products without adequately explaining the current lack of evidence. Worrying statements that were reported to us fell into several broad categories. Firstly, there were recommendations from pharmacy staff:

“It brings the body back into homeostasis”

“I have had a number of people tell me it really helped”

“I asked if it was good – she said that it was very good. I asked if it was effective – she said that they were all effective and that the store sold a lot of those products. I asked if it was as good as prescription medication. She said that the sleeping aids would not knock you right out, but otherwise they were all superior to prescription medication. I asked why they were superior, she said because they can never do any harm and that many prescription remedies cause liver damage and / or addiction.”

“When asked if they were as effective, she said that it has to do with your belief system.”

“When asked how the homeopathic remedy that she could order in for me works she said that it would help my body to heal itself”

“The staff member told me that these products worked, and that science was starting to show this. She dismissed the idea that they only work as well as placebo, and insisted that they have a real effect.”

“I was told by a staff member from behind the prescription counter that homeopathy works, and that its extensive historical use was evidence of this. I was also told that the number of customers they have buying homeopathic products was testament to its efficacy.”

“different to normal medicine but with a mix of ingredients that would help”

“I asked about homeopathic sleep drops on the shelf below and was told they definitely work.”

“The pharmacist told me that the Weleda Cold & Flu remedy would absolutely help with a cold, and with flu symptoms as well. He said that I should take a large initial dose that would help me recover quicker.”

“he has no problem with recommending the Weleda products to customers”

“She said that Arnica was an absolute must-have, and then proceeded to take me to a section and offer me several bottles of different concoctions, all of which ad 9c or 10c after them, which I recognised as the symbol for incredible amounts of dilution”

“The pharmacist confirmed this was a homeopathic product and then started out by saying they had several mothers that swear by this product”

“was recommended a homeopathic sleep remedy”

“I was told that homeopathy would help with a cold, and that it works “holistically”. I was also recommended vitamin C, echinacea and aged garlic to treat the symptoms.”

“Three products were recommended for a cold. I was told it worked for the staff member’s son, better than any other medicine. I was told that echinacea would definitely treat my cold”

“I was told that homeopathic Weleda Echinacea would help lessen the length of a cold, and that homeopathy helps by boosting the immune system. The staff member also tried to sell me high dose vitamin C and a Go-Vir supplement.”

Next were staff members who weren’t sure what homeopathy was (In fairness, some of these pharmacies didn’t stock homeopathy):

“he was almost totally ignorant of the subject and thought it had active ingredients”

“the assistant had little knowledge or awareness about homeopathy thinking this was instead ‘natural’ or ‘herbal’ and directed me to these products instead”

“the younger ones simply had no idea what any of these things were”

“the staff member didn’t really seem to know what I was talking about”

“She said because they were natural, I asked her if she knew what was in them or how they worked. She said she would get her manager”

“the assistant had to ask the Pharmacist as she didn’t know what homeopathy was”

“She said she wasn’t sure, but she thought homeopathic was probably different to natural”

“I was told that there’s no chemicals, and instead it’s plant extracts.”

Several pharmacies were happy to recommend visiting somewhere that would give a more positive outlook on homeopathy and/or a greater range:

“they didn’t stock that product, but I could find it at Health 2000”

“suggested I come back tomorrow when the expert on homoeopathy would be in the shop”

“the assistant had little knowledge about homeopathy and referred me to a natural health food shop”

“if a customer wanted homeopathy products she would refer them to a local homeopathy dispenser”

“She recommended “Health 2000” for a greater selection”

“Suggested Simillimum [a local homeopathic dispensary] if I was after homeopathy”

“I was redirected to a local spiritual/natural health store for more range, and told that I would get good advice there.”

The full text of the reports we received accompanies this submission.

It seems that some pharmacies did not stock homeopathy, but a significant number of others did have homeopathic products on their shelves and in most of these pharmacies staff were willing to offer homeopathy as a viable treatment, with no information offered about a lack of efficacy. It was only on further probing that a subset of these staff members were then willing to share their thoughts that homeopathy isn’t generally understood to be effective.

In the main, the reports we received painted a picture that many pharmacies are selling ineffective health products, and that staff are either reluctant to speak their mind about their lack of efficacy or have a mistaken belief that it works. This is echoed by a recent statement attributed to the Pharmacy Council’s chairman:

Pharmacy Council chairman Dr Andrew Bary said the rules as they stood were “unworkable” and many pharmacists, including himself, were already selling complementary medicines, even if they didn’t believe their claims.

This statement concerns us as it suggests that even the head of the Pharmacy Council does not take the Council’s Code of Ethics seriously. With the code being an important patient protection mechanism, we’re disappointed to see it so readily disregarded.

Given the evidence we collected of pharmacies offering not just homeopathy, but also other unproven treatments, we wonder if it would be wise for the Pharmacy Council to consider running their own “secret shopper” visits to New Zealand pharmacies to ensure a consistent high standard of service.

As well as these pharmacy visits, a quick search of New Zealand pharmacies online showed a worrying number of pharmacies outright promoting homeopathy for sale. Examples of homeopathy being promoted by these pharmacies online are:

“A popular service we provide are concise acute homeopathic consultations”

“a range of homeopathic medicines to treat a wide range of illnesses and concerns”

“Homeopathic remedies offer gentle solutions to common complaints without the nasty side effects of many drugs”

“an all-natural allergen-free homoeopathic formula that provides soothing support for wind, colic, upset stomach, bloating and hiccups”

“[Homeopathic] tablets help the body cope with tobacco cravings and are a useful substitute for cigarettes”

“Weleda ARNICA 30C… Used to treat bruising and sprains”

“Treatments such as homeopathy… may be great avenues to consider if you’re suffering from chronic illness.”

More information about these websites accompanies this submission.

Pharmacies are in a privileged position in today’s healthcare industry, where the advice of pharmacy staff is trusted by patients. This position has been well earned, with a long history of highly trained professional pharmacists and other pharmacy staff giving valuable advice to patients. The Pharmacy Council’s Code of Ethics says as much in the introduction to Principle 6:

Patients, colleagues and the public place their trust in you as a pharmacy professional.

This trust will inevitably extend to the products on a pharmacy’s shelves – many people will believe that if a pharmacy is selling a product, there must be good evidence of efficacy. People will assume that because pharmacists are known to have the best interests of their patients at heart, they would not be willing to supply anything lacking in clinical evidence of efficacy.

The Pharmacy Council consultation document clearly states that:

In instances where there is credible evidence to suggest a specific complementary and/or alternative medicine/product lacks efficacy, pharmacists should not promote or recommend its use.

We agree with this, and think that it would make a valuable addition to the code if “supply” is added. This paragraph regarding products where there is evidence of a lack of efficacy would make a good counterpoint to the existing clause, which talks of products with a lack of evidence of efficacy.

Additionally, as a part of this new clause, we would like to see provision for either the Pharmacy Council or another related body to maintain a list of classes of products where it is deemed that there is credible evidence of a lack of efficacy. This list would both help pharmacies to avoid unintentionally breaching the Council’s code of ethics, and would save individual pharmacists having to do their own time consuming research into these products. It is much more efficient, and would be a much more robust solution, if this research was performed once by a group of experts under the care of the Pharmacy Council, and that information was then shared with all pharmacies.

The document says that “It is not Council’s intention to endorse or prohibit the supply of any particular complementary and/or alternative medicine or product”. Whereas we understand that not endorsing a product is a wise stance, prohibiting the supply of products or classes of products that are ineffective, or even just recommending that pharmacies refrain from supplying them, would seem like a good way to ensure that pharmacies can easily abide by their Code of Ethics without having to try to figure out the Pharmacy Council’s intention. We support any measures the Pharmacy Council take that will make it easier for pharmacies to interpret the Council’s various codes, and it seems obvious that there is a need for clarity regarding clause 6.9 of the Code of Ethics.

Finally, the Council’s consultation document says that “Pharmacists must also respect patients’ rights to freedom of choice or autonomy in relation to their treatment options”. We hope that the Council understands that people’s freedom of choice would not be removed if pharmacies stopped selling unproven treatments. There are many other avenues in New Zealand where patients would continue to be able to purchase these products. As an example, pharmacies generally don’t sell therapeutic magnetic bracelets, as these are considered not to be efficacious, but they are still available for New Zealanders to buy at alternative health stores and online sites.

In conclusion, we do not support the Council’s wording of the proposed supplementary clause to section 6.9 of the Pharmacy Council Code of Ethics 2011. We are concerned with the Council’s motivation for making this change, and would prefer to see the current wording both kept and enforced. We would also like to see a different supplementary clause (6.9b) to the Council’s suggested clause added:

6.9a Only purchase, supply or promote any medicine, complementary therapy, herbal remedy or other healthcare product where there is no reason to doubt its quality or safety and when there is credible evidence of efficacy.

6.9b Do not purchase, supply or promote any medicine, complementary therapy, herbal remedy or other healthcare product where there is credible evidence to suggest it lacks efficacy. A current list of these categories of products can be found <on the Pharmacy Council website / at http://www.pharmacycouncil.org.nz/xxxxxxx / in Appendix X>.

This submission has been prepared by the NZ Skeptics, and is approved by its Committee:

• Mark Honeychurch
• Barry Lennox
• Keith Garratt
• Matt Beavan
• Daniel Ryan
• Michael Edmonds
• Lisa Taylor
• Robert Woolf
• David Riddell
• Brad MacClure
• Vicki Hyde
• Craig Shearer